Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas

NCT ID: NCT00532441

Last Updated: 2016-02-12

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 25 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-09-30
• Study Completion Date: 2010-08-31

Brief Summary

An unmet medical need exists for the successful therapy of patients with advanced hepatocellular and biliary tract malignances, with few and short lived disease responses to chemotherapy for both advanced stage hepatic and biliary carcinomas. Pre-clinical data shows cooperative antitumor activity between an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor and taxanes. The efficacy of erlotinib in combination with docetaxel will be assessed in this trial.

Detailed Description

Outline: This is a multi-center study.

Patients who meet eligibility criteria will receive treatment as follows until disease progression or excessive toxicities:

• Erlotinib 150 mg p.o. daily on days 2-7, 9-14, 16-28
• Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8, 15

Treatment cycle = 28 days

Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2

Life expectancy: At least 12 weeks

Hematopoietic:

• Absolute neutrophil count (ANC) > 1000 mm3
• Platelet count > 75,000 mm3
• Hemoglobin > 8 g/dL

Hepatic:

• Bilirubin < 2.0 x upper limit of normal (ULN)
• Transaminases (AST, ALT) < 5.0 x ULN if alkaline phosphatase is < 2.5 x ULN, or alkaline phosphatase < 5 x ULN if transaminases are < 1.5 x ULN.
• If not on anticoagulation: PT < 4 seconds above ULN; INR < 1.5; PTT < 1.3 x ULN.
• If on therapeutic anticoagulation, patients may have an INR > 1.5 and PTT within therapeutic range; INR will be monitored weekly until stable.
• Serum Albumin > 3.0

Renal:

• Creatinine clearance of > 60 ml/ min (by Cockcroft-Gault)

Pulmonary:

• Not specified

Conditions

Hepatocellular Carcinoma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Erlotinib and Docetaxel: Biliary

Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28

Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15

Group Type: EXPERIMENTAL

Erlotinib

Intervention Type: DRUG

Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28

Docetaxel

Intervention Type: DRUG

Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15

Erlotinib and Docetaxel: Hepatocellular

Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28

Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15

Group Type: EXPERIMENTAL

Erlotinib

Intervention Type: DRUG

Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28

Docetaxel

Intervention Type: DRUG

Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15

Interventions

Erlotinib

Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28

Intervention Type: DRUG

Docetaxel

Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Histological or cytological proof of hepatocellular or biliary tract carcinomas, not amenable to curative resection or transplantation.
• Prior cancer treatment completed at least 30 days prior to being registered for protocol therapy and recovered from the acute toxicity effects of the regimen.
• Patients may have had radiofrequency ablation, cryosurgery or embolization, but must have documented progressive disease with the involved lesion, or at least one previously untreated lesion.
• Patients may have had ≤ 2 prior chemotherapy regimens.
• Prior radiation therapy allowed to < 25% of the bone marrow at least 30 days prior to being registered for protocol therapy.
• Patients with biliary obstruction must have percutaneous transhepatic drainage or endoscopic stent placement prior to starting study treatment.
• Patients with a history of malignancy are eligible provided they have been curatively treated and demonstrate no evidence for recurrence of that cancer.
• Peripheral neuropathy ≤ grade 1.
• Patients must agree to abstain from frozen or fresh grapefruit or grapefruit juice for 5 days prior to, and during treatment.
• Patients must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) while on treatment and for a 12 week period thereafter.
• Females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for protocol therapy.
• Written informed consent and HIPAA authorization for release of personal health information.
• Age ≥ 18 years at time of consent.

Exclusion Criteria

• No previous treatment with EGFR inhibitors.
• No treatment with any investigational agent within 30 days prior to being registered for protocol therapy.
• No symptomatic brain metastasis. A subject with prior brain metastasis may be considered if they have completed their treatment for brain metastasis, no longer require corticosteroids, and are asymptomatic.
• No Child-Pugh B or C liver cirrhosis.
• No active corneal erosions or history of abnormal corneal sensitivity test.
• No history of aneurysm or arteriovenous malformation.
• No hemorrhage/bleeding event > CTCAE Grade 3 within 30 days prior to begin registered for protocol therapy.
• No clinically significant infections as judged by the treating investigator.
• No condition that impairs patient's ability to swallow whole pills.
• No history of hypersensitivity to docetaxel or other drugs formulated with polysorbate 80.
• Females must not be breastfeeding.
• Patients who cannot avoid the following medications will be ineligible for the trial: midazolam, anti-mycotic agents (ketoconazole and related compounds), macrolide antibiotics (erythromycin and related compounds), nifedipine, phenobarbital, phenytoin, carbamazepine, and rifampin (induction) and anti-retrovirals (including ritonavir, saquinavir).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sanofi

INDUSTRY

Sponsor Role: collaborator

OSI Pharmaceuticals

INDUSTRY

Sponsor Role: collaborator

Gabi Chiorean, MD

OTHER

Sponsor Role: lead

Responsible Party

Gabi Chiorean, MD

Principal Investigator

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Elena Gabriela Chiorean, M.D.

Role: STUDY_CHAIR

Hoosier Oncology Group, LLC

Locations

Helen F. Graham Cancer Center

Newark, Delaware, United States

Northwestern University Feinberg School of Medicine

Chicago, Illinois, United States

Rush-Presbyterian St. Luke's Medical Center

Chicago, Illinois, United States

Cancer Care Center of Southern Indiana

Bloomington, Indiana, United States

Fort Wayne Oncology & Hematology, Inc

Fort Wayne, Indiana, United States

IN Onc/Hem Associates

Indianapolis, Indiana, United States

Indiana University Cancer Center

Indianapolis, Indiana, United States

Quality Cancer Center (MCGOP)

Indianapolis, Indiana, United States

Medical Consultants, P.C.

Muncie, Indiana, United States

Northern Indiana Cancer Research Consortium

South Bend, Indiana, United States

Siteman Cancer Center

St Louis, Missouri, United States

Methodist Cancer Center

Omaha, Nebraska, United States

Countries

United States

References

Chiorean EG, Ramasubbaiah R, Yu M, Picus J, Bufill JA, Tong Y, Coleman N, Johnston EL, Currie C, Loehrer PJ. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101. Oncologist. 2012;17(1):13. doi: 10.1634/theoncologist.2011-0253. Epub 2011 Dec 30.

Reference Type: RESULT

PMID: 22210086 (View on PubMed)

Related Links

http://www.hoosieroncologygroup.org

Hoosier Oncology Group Home Page

Other Identifiers

GI06-101

Identifier Type: -

Identifier Source: org_study_id